New Option to Help with Insulin Control
An Australian-first is launched in Melbourne today
Medtronic bringing the MiniMed 670G insulin pump to Australia.
The system, the only one of its kind in Australia, is designed to learn a person’s individual insulin needs and requires minimal input from the user.
It does this by measuring blood glucose levels every five minutes and takes action against high and low blood glucose levels. This means the user only needs to enter mealtime carbs, accept bolus corrections and conduct the occasional calibration of the sensor.
The new technology is really designed to simplify elements of type 1 diabetes (T1D) management that need to be done across a day, while still providing optimal control of blood glucose levels.
The system is approved in Australia for people living with T1D aged over seven who need at least eight units of insulin a day.
Commenting on the availability of the new device, JDRF CEO Mike Wilson, states;
“Technological advances have always been an important element in improving the management of type 1 diabetes. JDRF welcomes the availability of new technologies such as this system”.
Broadly speaking, new innovations and technologies have historically an important part of improving outcomes for people living with T1D. However for these new innovations to be available to the public, they first must be discovered. And this discovery and translation from a concept to a safe, viable product requires research. That is why JDRF was so pleased with last week’s announcement of $54.5 million for T1D research. Hot on the heels of the Australian Labor Party’s $50m commitment to fund the CRN, it shows that both sides of politics understand this too.
For more information on this device, visit the Medtronic Diabetes website.
Report: Aussie adults with type 1 diabetes unable to access life-changing technology due to high cost
Young adults and low-income families with type 1 diabetes (T1D) are facing immense barriers to using and retaining vital technology to manage their disease, with inequitable access and high costs putting them at risk of financial burden and life-threatening complications. The financial burden of managing T1D is exacerbating mental health issues with half of those […]
T1D Research Roundup: March 2021
Our research roundups bring you the most exciting T1D research stories from around the world – the new advances in treatment, devices and knowledge that are making the biggest impact in the fight to cure, treat and prevent T1D. Here’s what you need to know in T1D research this month: Monash University researchers crack the […]
COVID-19 Vaccines and T1D: Answering Your Questions
Australia has begun the rollout of two COVID-19 vaccines — one from Pfizer, and one from AstraZeneca. Both these vaccines are safe and effective at protecting people against COVID-19, and all Australians are encouraged to get vaccinated. With vaccines beginning to be offered to people with T1D, we’ve gathered all the information you need to […]
Top 10 T1D Research Breakthroughs of 2020
While COVID-19 has dominated the news in 2020, it’s also been a huge year for type 1 diabetes research. This year, we’ve made more progress than ever on our mission to cure, treat and prevent T1D – including new insights into what causes the disease, some incredible results from prevention therapies, and the launch of […]